What smart money is saying about Immunome Inc.
1 fund in our archive has pitched Immunome Inc. — most recently Aristotle Core Equity in March 2026.
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is developing IMM-BCP-01, an experimental antibody cocktail designed for the management of SARS-CoV-2 infections and COVID-19. This enterprise was founded in 2006 and its principal operations are based in Exton, Pennsylvania.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Immunome Inc. on record in the archive was reported in Q1 2026, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q1 2026 | 1 | 1 | 0 | 1 |
Fund activity · 1 position · 1 move
- New positionAristotle Core EquityMarch 2026
“Immunome Immunome Inc. is a biotechnology company focused on developing innovative therapies by combining unique or underexplored biological targets with advanced technology platforms. The organization is guided by President and Chief Executive Officer Clay Siegall, Ph.D., who previously founded and led SeaGen and is recognized for his experience in growing oncology businesses and securing significant acquisitions. The leadership team is composed of experts with backgrounds in designing, developing and commercializing cancer treatments. Immunome’s portfolio includes three clinical-stage drug candidates. The company is also advancing several preclinical programs. We believe Immunome presents a compelling investment opportunity, driven by its focus on personalized medicine and the promising product story of Varegacestat for desmoid tumors.”
Immunome Inc.
Fund coverage · 1 thesis
- Aristotle Core EquityMarch 2026
Immunome Inc. is a biotech led by experienced management with a desmoid tumor therapy nearing FDA filing, sizable market potential, and ample cash.
Read the full thesis
Read every full thesis on Immunome Inc.
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→